Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.
about
Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIsA three-drug combination to treat BRAF-mutant cancers.Ginkgetin induces autophagic cell death through p62/SQSTM1-mediated autolysosome formation and redox setting in non-small cell lung cancer.SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small cell lung cancer: AURA3 trial.A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors.
P2860
Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Targeting the Gatekeeper: Osim ...... ve Non-Small Cell Lung Cancer.
@en
Targeting the Gatekeeper: Osim ...... ve Non-Small Cell Lung Cancer.
@nl
type
label
Targeting the Gatekeeper: Osim ...... ve Non-Small Cell Lung Cancer.
@en
Targeting the Gatekeeper: Osim ...... ve Non-Small Cell Lung Cancer.
@nl
prefLabel
Targeting the Gatekeeper: Osim ...... ve Non-Small Cell Lung Cancer.
@en
Targeting the Gatekeeper: Osim ...... ve Non-Small Cell Lung Cancer.
@nl
P1476
Targeting the Gatekeeper: Osim ...... ve Non-Small Cell Lung Cancer.
@en
P2093
Ferdinandos Skoulidis
P304
P356
10.1158/1078-0432.CCR-15-2815
P407
P577
2016-11-07T00:00:00Z